Código QR (código de barras bidimensional)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a...

Fuld beskrivelse

Na minha lista:
Principais autores: Ralph E. White, Maxwell Bannister, Abderrahman Day, Hannah E. Bergom, Victor M. Tan, Justin Hwang, Hai Dang Nguyen, Justin M. Drake
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2023-06-01
Serier:Frontiers in Oncology
Fag:
prostate cancer
enzalutamide
SRC kinase inhibitor
Synergy
androgen receptor
phosphorylation
Online adgang:https://www.frontiersin.org/articles/10.3389/fonc.2023.1210487/full
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker